Issue link: http://read.uberflip.com/i/1513142
Introduction Disruption is the theme of the TELUS Health 2023 Category Watch report. The categories of diabetes, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis have experienced explosive growth in recent years, fuelled by factors such as off-label prescribing, better health outcomes—even life-changing health outcomes—and growing patient populations. Drawing from its database of privately insured individuals, which surpassed 12.7 million in 2022, TELUS Health pulls together analytics and expert analysis to spell out key trends in claims, claimants and eligible amounts. Without exception, the categories of diabetes, ADHD and cystic fibrosis are experiencing transformative change. Also without exception, the handful of drugs driving such change represent advancements in treatment that can significantly improve quality of life—including productivity in the workplace. Their impact on drug spend is also eye-opening. Combined, the total eligible amount for these three drug categories more than doubled from 2018 to 2022, surpassing $1.1 billion in TELUS Health's book of business. The value of these medications for patients and employers is without question. At the same time, measures to optimize adherence, monitor utilization and support wellness more holistically are more important than ever," says Vicky Lee, Manager, Pharmacy Consulting, TELUS Health. P. 3